Replies to post #105904 on Anavex Life Sciences Corp (AVXL)

[Talon38]

Kid, Potential is the operable word. However, no drug even gets to use that word until it shows preclinical "potential". Let's see where these studies lead. If only 50% are successful we have a "winner".

[PeterKarol]

Well, remember the mouse models of AD and the strong results by 57 week, considering the variable dosage and the tweaking of the adaptive sort, The mouse model predicted the human trial results. But to see through the maze of graphs and blanket statements of reaching objectives without any detail is to see the delayed 15 months result as obvious prove of reversed AD. The mouse models have me excited as far as all other maladies they predict A2-73 to be almost CNS panaceas. Latest news in very circumspect way hints at very broad systemic effect. There is more evidence of benefits to CNS yet the exact MOA is not well understood. Maybe that is why Adam F is so dismissive of A2-73 as he errs on the side "of all sigma one drugs are the same". Modern drug finding goes the way of designing drug to physiological process. For BP and FDA MOA in light of the modern search for cures is essential to have "predicable" and save drug. Something which works wonders within black box is disconcerting . Dr M is building the case for either acceptance of A2-73 or better bargaining position even without exact MOA. The 15 month news is a historical event as the world will find out that there is a way to reverse AD.